Fusion protein having enhanced in vivo erythropoietin activity

Details Fusion protein having enhanced in vivo erythropoietin activity Fusion protein having enhanced in vivo erythropoietin activity

C - Chemistry, Metallurgy

12

N

C12N 15/62 (2006.01) C07K 14/505 (2006.01) C07K 14/59 (2006.01) C07K 19/00 (2006.01) C12N 5/10 (2006.01) C12N 15/63 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2400908

Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) .beta. subunit, for increasing an in vivo half-life activity of EPO. The in vivo half- life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.

Protéine de fusion comportant, à son extrémité carboxylique d'érythropoïétine humaine (EPO), un mutant présentant une à quatre substitutions d'acides aminés dans le fragment de peptide d'extrémité carboxylique (CTP) d'une sous-unité bêta de gonadotrophine chorionique humaine (HCG) pour augmenter l'activité de demi-vie in vivo de l'EPO. Il est possible de grandement prolonger la demi-vie in vivo de l'EPO tout en maintenant son activité intrinsèque, sans augmenter la teneur en glucides.

Affiliated with

Also associated with

Rating

Fusion protein having enhanced in vivo erythropoietin activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion protein having enhanced in vivo erythropoietin activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein having enhanced in vivo erythropoietin activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1415974